The DOI matches its Crossref record; 146 of the 146 references it cites were found in a registry or an index.
Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoclast differentiation and activation
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003) · Nature · doi:10.1038/nature01658 · Cited by 6,670
Self-citationOsteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Self-citationMetastasis to bone: causes, consequences and therapeutic opportunities
Mundy, G. R. (2002) · Nature Reviews Cancer · doi:10.1038/nrc867 · Cited by 2,777
Roodman, G. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra030831 · Cited by 2,755
Kanis, J. A., & Kanis, J. A. (1994) · Osteoporosis International · doi:10.1007/bf01622200 · Cited by 2,516
Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483
Self-citation
Cited by
Ruggiero, S. L., Dodson, T. B., Fantasia, J., Goodday, R., Aghaloo, T., Mehrotra, B., & O'Ryan, F. (2014) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2014.04.031 · Cited by 2,905
Ruggiero, S. L., Dodson, T. B., Aghaloo, T., Carlson, E. R., Ward, B. B., & Kademani, D. (2022) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2022.02.008 · Cited by 1,141
Osteoporosis treatment: recent developments and ongoing challenges
Khosla, S., & Hofbauer, L. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30188-2 · Cited by 1,019
Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond
Walsh, M. C., & Choi, Y. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00511 · Cited by 599
The TNF Family of Ligands and Receptors: Communication Modules in the Immune System and Beyond
Dostert, C., Grusdat, M., Letellier, E., & Brenner, D. (2019) · Physiological Reviews · doi:10.1152/physrev.00045.2017 · Cited by 498
Getting TRAIL back on track for cancer therapy
Lemke, J., von Karstedt, S., Zinngrebe, J., & Walczak, H. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.81 · Cited by 457
Clinical targeting of the TNF and TNFR superfamilies
Croft, M., Benedict, C. A., & Ware, C. F. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3930 · Cited by 456
Tertiary lymphoid structures, drivers of the anti‐tumor responses in human cancers
Dieu‐Nosjean, M., Giraldo, N. A., Kaplon, H., Germain, C., Fridman, W. H., & Sautès‐Fridman, C. (2016) · Immunological Reviews · doi:10.1111/imr.12405 · Cited by 417
Bone metastasis: mechanisms, therapies, and biomarkers
Clézardin, P., Coleman, R., Puppo, M., Ottewell, P., Bonnelye, E., Paycha, F., Confavreux, C. B., & Holen, I. (2021) · Physiological Reviews · doi:10.1152/physrev.00012.2019 · Cited by 416
Osteoclasts: more than ‘bone eaters’
Charles, J. F., & Aliprantis, A. O. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.06.001 · Cited by 391
LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption
Luo, J., Yang, Z., Ma, Y., Yue, Z., Lin, H., Qu, G., Huang, J., Dai, W., Li, C., Zheng, C., et al. (2016) · Nature Medicine · doi:10.1038/nm.4076 · Cited by 370
RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass
Bonnet, N., Bourgoin, L., Biver, E., Douni, E., & Ferrari, S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125915 · Cited by 314
Molecular Mechanisms and Emerging Therapeutics for Osteoporosis
Noh, J.-Y., Yang, Y., & Jung, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207623 · Cited by 287
RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives
Infante, M., Fabi, A., Cognetti, F., Gorini, S., Caprio, M., & Fabbri, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-1001-2 · Cited by 180
Osteoporosis in patients with chronic kidney diseases: A systemic review
Hsu, C.-Y., Chen, L.-R., & Chen, K.-H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186846 · Cited by 162
Treatment with Zoledronate Subsequent to Denosumab in Osteoporosis: a Randomized Trial
Sølling, A. S., Harsløf, T., & Langdahl, B. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4098 · Cited by 111
Cui, Y., Lv, B., Li, Z., Ma, C., Gui, Z., Geng, Y., Liu, G., Sang, L., Xu, C., Min, Q., et al. (2024) · Small · doi:10.1002/smll.202303494 · Cited by 81
RANKL/RANK: from bone loss to the prevention of breast cancer
Sigl, V., Jones, L. P., & Penninger, J. M. (2016) · Open Biology · doi:10.1098/rsob.160230 · Cited by 76
Osteoprotegerin Protects against Muscular Dystrophy
Dufresne, S. S., Dumont, N. A., Bouchard, P., Lavergne, É., Penninger, J. M., & Frenette, J. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.01.006 · Cited by 61
RANKL/RANK pathway and its inhibitor RANK-Fc in uterine leiomyoma growth
Ikhena, D. E., Liu, S., Kujawa, S., Esencan, E., Coon, J. S., Robins, J., Bulun, S. E., & Yin, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01585 · Cited by 26
A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor
Ko, Y. J., Sohn, H. M., Jang, Y., Park, M., Kim, B., Kim, B., Park, J., Hyun, H., Jeong, B., Hong, C., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.368 · Cited by 23
Metadata
- Authors
- Lacey, D. L., Boyle, W. J., Simonet, W. S., Kostenuik, P. J., Dougall, W. C., Sullivan, J. K., Martin, J. S., & Dansey, R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-05
- Volume
- 11
- Issue
- 5
- Pages
- 401-419
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2137830201
- Cited by
- 694
- References
- 146
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.